Welcome to AiCuris: The Powerhouse for Anti-infectives    

 

“Committed to making the difference”

AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).

Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.

About the NDR report

About the NDR report: AiCuris remains fully committed to the fight against multidrug-resistant bacteria

The NDR is currently reporting in „Tagesschau“ and in the magazine „Panorama“ on the growing threat of multidrug-resistant germs in which antibiotics currently on the market are no longer effective. In addition, more and more pharmaceutical companies are withdrawing from the development of new active ingredients but this is not true for AiCuris. Read statement (in German)

Read more ...

PREVYMIS® at Deutsches Museum

Letermovir project by AiCuris becomes part of the permanent exhibition at the Deutsches Museum in Munich

The Letermovir project, which was awarded the German Future Prize 2018, will be on public display for the next ten years at the Deutsches Museum.
The winners, Prof. Dr. Helga Rübsamen-Schaeff, founding CEO, and Dr. Holger Zimmermann, CEO of AiCuris Anti-Infective Cures GmbH, unveiled the module yesterday at a festive event.

Read more ...

Cooperation with Lysando

AiCuris and Lysando join forces in the fight against antimicrobial resistance

Lysando AG and AiCuris today annouced the signing of a long-term cooperation for the development and optimization of Artilysin®-based drug candidates for various anti-bacterial indications.

Read more ...